The Silvi Foundation has officially launched as a nonprofit organization dedicated to advancing research into Parkinson’s disease and other neurodegenerative conditions. As its first initiative, the newly established foundation has awarded a $100,000 grant to the Institute for Neurodegenerative Diseases (IND) to support research on blood-based biomarkers…

Despite strong evidence linking paraquat to Parkinson’s disease, the herbicide is still legal in the U.S., although some states are moving to restrict or ban it to protect public health. Advocates, including the American Parkinson’s Disease Association (APDA), are also urging action to align federal policy with more…

Depression that starts later in life could be an early clinical manifestation of Parkinson’s disease and the related condition dementia with Lewy bodies (DLB), according to a study, which found that people who were diagnosed with either of these conditions had significantly higher rates of incident depression than…

A clinical trial testing Teitur Trophics‘ TT-P34 in Parkinson’s disease will use Neuralight‘s brain function biomarker based on eye movement to assess neural circuitry, the companies announced. Neuralight’s platform provides precise measures of brain function derived from eye movements, based on well-established links between specific eye movement…

A $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will help Booster Therapeutics develop therapeutics to improve the body’s ability to clear disease-causing proteins that drive Parkinson’s disease. The research grant will support studies into small-molecule therapeutics that activate the proteasome, a cellular…

For the first time, scientists have managed to visualize tiny protein clumps in the brain that are thought to trigger Parkinson’s disease, opening the door for new insights into how the condition develops. In a study detailing their work, the team presented an imaging method able to “generate large-scale…

WTX-607, an oral small molecule being developed by Wavebreak, binds to and blocks the formation of small alpha-synuclein protein clumps — toxic aggregates linked to nerve damage in  Parkinson’s disease and Lewy body dementia — in human brain tissue, according to new data released by the company. The…

People diagnosed with Parkinson’s disease in their 80s were significantly more likely to show evidence of brain buildup of amyloid-beta, a protein linked to cognitive decline in Alzheimer’s disease, than those diagnosed at a younger age, a study found. Neither group showed signs of cognitive impairment. The researchers…

An international team of scientists has identified imaging biomarkers that can predict which people with REM sleep behavior disorder (RBD) will develop Parkinson’s disease, or who might progress to dementia with Lewy bodies (DLB). Most individuals with RBD — a sleep disorder in which people unknowingly act out…

Researchers have shed light on how alpha-synuclein oligomers, small soluble protein clusters linked to Parkinson’s disease, may disrupt nerve cell function by forming dynamic, reversible pores in their cell membrane. By developing a novel assay that enabled real-time visualization of how these oligomers interact with tiny artificial vesicles resembling…